Report Cover

Global Oncology Biosimilars Market Research Report 2021


The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
    Monoclonal Antibody
    Hematopoietic Agents
    G-CSF
    Others

Segment by Application
    Retail Pharmacies
    Hospital Pharmacy
    Online Pharmacy

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        U.A.E

By Company
    Celltrion
    Biocon
    Dr. Reddy's Laboratories
    STADA Arzneimittel AG
    Intas Pharmaceuticals
    Pfizer
    Sandoz International
    Teva Pharmaceutical Industries Ltd
    Apotex
    BIOCAD
1 Oncology Biosimilars Market Overview
    1.1 Product Overview and Scope of Oncology Biosimilars
    1.2 Oncology Biosimilars Segment by Type
        1.2.1 Global Oncology Biosimilars Sales Growth Rate Comparison by Type (2021-2027)
        1.2.2 Monoclonal Antibody
        1.2.3 Hematopoietic Agents
        1.2.4 G-CSF
        1.2.5 Others
    1.3 Oncology Biosimilars Segment by Application
        1.3.1 Oncology Biosimilars Sales Comparison by Application: (2021-2027)
        1.3.2 Retail Pharmacies
        1.3.3 Hospital Pharmacy
        1.3.4 Online Pharmacy
    1.4 Global Oncology Biosimilars Market Size Estimates and Forecasts
        1.4.1 Global Oncology Biosimilars Revenue 2016-2027
        1.4.2 Global Oncology Biosimilars Sales 2016-2027
        1.4.3 Oncology Biosimilars Market Size by Region: 2016 Versus 2021 Versus 2027

2 Oncology Biosimilars Market Competition by Manufacturers
    2.1 Global Oncology Biosimilars Sales Market Share by Manufacturers (2016-2021)
    2.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2016-2021)
    2.3 Global Oncology Biosimilars Average Price by Manufacturers (2016-2021)
    2.4 Manufacturers Oncology Biosimilars Manufacturing Sites, Area Served, Product Type
    2.5 Oncology Biosimilars Market Competitive Situation and Trends
        2.5.1 Oncology Biosimilars Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Oncology Biosimilars Players Market Share by Revenue
        2.5.3 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Oncology Biosimilars Retrospective Market Scenario by Region
    3.1 Global Oncology Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
    3.2 Global Oncology Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
    3.3 North America Oncology Biosimilars Market Facts & Figures by Country
        3.3.1 North America Oncology Biosimilars Sales by Country
        3.3.2 North America Oncology Biosimilars Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Oncology Biosimilars Market Facts & Figures by Country
        3.4.1 Europe Oncology Biosimilars Sales by Country
        3.4.2 Europe Oncology Biosimilars Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Oncology Biosimilars Market Facts & Figures by Region
        3.5.1 Asia Pacific Oncology Biosimilars Sales by Region
        3.5.2 Asia Pacific Oncology Biosimilars Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Oncology Biosimilars Market Facts & Figures by Country
        3.6.1 Latin America Oncology Biosimilars Sales by Country
        3.6.2 Latin America Oncology Biosimilars Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country
        3.7.1 Middle East and Africa Oncology Biosimilars Sales by Country
        3.7.2 Middle East and Africa Oncology Biosimilars Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 U.A.E
4 Global Oncology Biosimilars Historic Market Analysis by Type
    4.1 Global Oncology Biosimilars Sales Market Share by Type (2016-2021)
    4.2 Global Oncology Biosimilars Revenue Market Share by Type (2016-2021)
    4.3 Global Oncology Biosimilars Price by Type (2016-2021)

5 Global Oncology Biosimilars Historic Market Analysis by Application
    5.1 Global Oncology Biosimilars Sales Market Share by Application (2016-2021)
    5.2 Global Oncology Biosimilars Revenue Market Share by Application (2016-2021)
    5.3 Global Oncology Biosimilars Price by Application (2016-2021)

6 Key Companies Profiled
    6.1 Celltrion
        6.1.1 Celltrion Corporation Information
        6.1.2 Celltrion Description and Business Overview
        6.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.1.4 Celltrion Product Portfolio
        6.1.5 Celltrion Recent Developments/Updates
    6.2 Biocon
        6.2.1 Biocon Corporation Information
        6.2.2 Biocon Description and Business Overview
        6.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.2.4 Biocon Product Portfolio
        6.2.5 Biocon Recent Developments/Updates
    6.3 Dr. Reddy's Laboratories
        6.3.1 Dr. Reddy's Laboratories Corporation Information
        6.3.2 Dr. Reddy's Laboratories Description and Business Overview
        6.3.3 Dr. Reddy's Laboratories Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.3.4 Dr. Reddy's Laboratories Product Portfolio
        6.3.5 Dr. Reddy's Laboratories Recent Developments/Updates
    6.4 STADA Arzneimittel AG
        6.4.1 STADA Arzneimittel AG Corporation Information
        6.4.2 STADA Arzneimittel AG Description and Business Overview
        6.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 STADA Arzneimittel AG Product Portfolio
        6.4.5 STADA Arzneimittel AG Recent Developments/Updates
    6.5 Intas Pharmaceuticals
        6.5.1 Intas Pharmaceuticals Corporation Information
        6.5.2 Intas Pharmaceuticals Description and Business Overview
        6.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.5.4 Intas Pharmaceuticals Product Portfolio
        6.5.5 Intas Pharmaceuticals Recent Developments/Updates
    6.6 Pfizer
        6.6.1 Pfizer Corporation Information
        6.6.2 Pfizer Description and Business Overview
        6.6.3 Pfizer Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.6.4 Pfizer Product Portfolio
        6.6.5 Pfizer Recent Developments/Updates
    6.7 Sandoz International
        6.6.1 Sandoz International Corporation Information
        6.6.2 Sandoz International Description and Business Overview
        6.6.3 Sandoz International Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 Sandoz International Product Portfolio
        6.7.5 Sandoz International Recent Developments/Updates
    6.8 Teva Pharmaceutical Industries Ltd
        6.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
        6.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
        6.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.8.4 Teva Pharmaceutical Industries Ltd Product Portfolio
        6.8.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
    6.9 Apotex
        6.9.1 Apotex Corporation Information
        6.9.2 Apotex Description and Business Overview
        6.9.3 Apotex Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.9.4 Apotex Product Portfolio
        6.9.5 Apotex Recent Developments/Updates
    6.10 BIOCAD
        6.10.1 BIOCAD Corporation Information
        6.10.2 BIOCAD Description and Business Overview
        6.10.3 BIOCAD Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
        6.10.4 BIOCAD Product Portfolio
        6.10.5 BIOCAD Recent Developments/Updates

7 Oncology Biosimilars Manufacturing Cost Analysis
    7.1 Oncology Biosimilars Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Oncology Biosimilars
    7.4 Oncology Biosimilars Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Oncology Biosimilars Distributors List
    8.3 Oncology Biosimilars Customers

9 Oncology Biosimilars Market Dynamics
    9.1 Oncology Biosimilars Industry Trends
    9.2 Oncology Biosimilars Growth Drivers
    9.3 Oncology Biosimilars Market Challenges
    9.4 Oncology Biosimilars Market Restraints

10 Global Market Forecast
    10.1 Oncology Biosimilars Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2022-2027)
        10.1.2 Global Forecasted Revenue of Oncology Biosimilars by Type (2022-2027)
    10.2 Oncology Biosimilars Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Oncology Biosimilars by Application (2022-2027)
        10.2.2 Global Forecasted Revenue of Oncology Biosimilars by Application (2022-2027)
    10.3 Oncology Biosimilars Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Oncology Biosimilars by Region (2022-2027)
        10.3.2 Global Forecasted Revenue of Oncology Biosimilars by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables Table 1. Global Oncology Biosimilars Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Oncology Biosimilars Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Oncology Biosimilars Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Oncology Biosimilars Covered in This Study Table 5. Global Oncology Biosimilars Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Oncology Biosimilars Sales Share by Manufacturers (2016-2021) Table 7. Global Oncology Biosimilars Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Oncology Biosimilars Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Oncology Biosimilars Average Price (US$/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Oncology Biosimilars Manufacturing Sites and Area Served Table 11. Manufacturers Oncology Biosimilars Product Type Table 12. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Biosimilars as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Oncology Biosimilars Sales by Region (2016-2021) & (K Units) Table 16. Global Oncology Biosimilars Sales Market Share by Region (2016-2021) Table 17. Global Oncology Biosimilars Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Oncology Biosimilars Sales by Country (2016-2021) & (K Units) Table 19. North America Oncology Biosimilars Sales Market Share by Country (2016-2021) Table 20. North America Oncology Biosimilars Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Oncology Biosimilars Revenue Market Share by Country (2016-2021) Table 22. Europe Oncology Biosimilars Sales by Country (2016-2021) & (K Units) Table 23. Europe Oncology Biosimilars Sales Market Share by Country (2016-2021) Table 24. Europe Oncology Biosimilars Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Oncology Biosimilars Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Oncology Biosimilars Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Oncology Biosimilars Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Oncology Biosimilars Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Oncology Biosimilars Revenue Market Share by Region (2016-2021) Table 30. Latin America Oncology Biosimilars Sales by Country (2016-2021) & (K Units) Table 31. Latin America Oncology Biosimilars Sales Market Share by Country (2016-2021) Table 32. Latin America Oncology Biosimilars Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Oncology Biosimilars Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Oncology Biosimilars Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Oncology Biosimilars Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Oncology Biosimilars Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Oncology Biosimilars Revenue Market Share by Country (2016-2021) Table 38. Global Oncology Biosimilars Sales (K Units) by Type (2016-2021) Table 39. Global Oncology Biosimilars Sales Market Share by Type (2016-2021) Table 40. Global Oncology Biosimilars Revenue (Million US$) by Type (2016-2021) Table 41. Global Oncology Biosimilars Revenue Share by Type (2016-2021) Table 42. Global Oncology Biosimilars Price (US$/Unit) by Type (2016-2021) Table 43. Global Oncology Biosimilars Sales (K Units) by Application (2016-2021) Table 44. Global Oncology Biosimilars Sales Market Share by Application (2016-2021) Table 45. Global Oncology Biosimilars Revenue (Million US$) by Application (2016-2021) Table 46. Global Oncology Biosimilars Revenue Share by Application (2016-2021) Table 47. Global Oncology Biosimilars Price (US$/Unit) by Application (2016-2021) Table 48. Celltrion Corporation Information Table 49. Celltrion Description and Business Overview Table 50. Celltrion Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 51. Celltrion Oncology Biosimilars Product Table 52. Celltrion Recent Developments/Updates Table 53. Biocon Corporation Information Table 54. Biocon Description and Business Overview Table 55. Biocon Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 56. Biocon Oncology Biosimilars Product Table 57. Biocon Recent Developments/Updates Table 58. Dr. Reddy's Laboratories Corporation Information Table 59. Dr. Reddy's Laboratories Description and Business Overview Table 60. Dr. Reddy's Laboratories Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 61. Dr. Reddy's Laboratories Oncology Biosimilars Product Table 62. Dr. Reddy's Laboratories Recent Developments/Updates Table 63. STADA Arzneimittel AG Corporation Information Table 64. STADA Arzneimittel AG Description and Business Overview Table 65. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 66. STADA Arzneimittel AG Oncology Biosimilars Product Table 67. STADA Arzneimittel AG Recent Developments/Updates Table 68. Intas Pharmaceuticals Corporation Information Table 69. Intas Pharmaceuticals Description and Business Overview Table 70. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 71. Intas Pharmaceuticals Oncology Biosimilars Product Table 72. Intas Pharmaceuticals Recent Developments/Updates Table 73. Pfizer Corporation Information Table 74. Pfizer Description and Business Overview Table 75. Pfizer Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 76. Pfizer Oncology Biosimilars Product Table 77. Pfizer Recent Developments/Updates Table 78. Sandoz International Corporation Information Table 79. Sandoz International Description and Business Overview Table 80. Sandoz International Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 81. Sandoz International Oncology Biosimilars Product Table 82. Sandoz International Recent Developments/Updates Table 83. Teva Pharmaceutical Industries Ltd Corporation Information Table 84. Teva Pharmaceutical Industries Ltd Description and Business Overview Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 86. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Table 87. Teva Pharmaceutical Industries Ltd Recent Developments/Updates Table 88. Apotex Corporation Information Table 89. Apotex Description and Business Overview Table 90. Apotex Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 91. Apotex Oncology Biosimilars Product Table 92. Apotex Recent Developments/Updates Table 93. BIOCAD Corporation Information Table 94. BIOCAD Description and Business Overview Table 95. BIOCAD Oncology Biosimilars Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 96. BIOCAD Oncology Biosimilars Product Table 97. BIOCAD Recent Developments/Updates Table 98. Production Base and Market Concentration Rate of Raw Material Table 99. Key Suppliers of Raw Materials Table 100. Oncology Biosimilars Distributors List Table 101. Oncology Biosimilars Customers List Table 102. Oncology Biosimilars Market Trends Table 103. Oncology Biosimilars Growth Drivers Table 104. Oncology Biosimilars Market Restraints Table 105. Global Oncology Biosimilars Sales Forecast by Type (2022-2027) & (K Units) Table 106. Global Oncology Biosimilars Sales Market Share Forecast by Type (2022-2027) Table 107. Global Oncology Biosimilars Revenue Forecast by Type (2022-2027) & (US$ Million) Table 108. Global Oncology Biosimilars Revenue Market Share Forecast by Type (2022-2027) Table 109. Global Oncology Biosimilars Sales Forecast by Application (2022-2027) & (K Units) Table 110. Global Oncology Biosimilars Sales Market Share Forecast by Application (2022-2027) Table 111. Global Oncology Biosimilars Revenue Forecast by Application (2022-2027) & (US$ Million) Table 112. Global Oncology Biosimilars Revenue Market Share Forecast by Application (2022-2027) Table 113. Global Oncology Biosimilars Sales Forecast by Region (2022-2027) & (K Units) Table 114. Global Oncology Biosimilars Sales Market Share Forecast by Region (2022-2027) Table 115. Global Oncology Biosimilars Revenue Forecast by Region (2022-2027) & (US$ Million) Table 116. Global Oncology Biosimilars Revenue Market Share Forecast by Region (2022-2027) Table 117. Research Programs/Design for This Report Table 118. Key Data Information from Secondary Sources Table 119. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Oncology Biosimilars Figure 2. Global Oncology Biosimilars Market Share by Type in 2020 & 2027 Figure 3. Monoclonal Antibody Product Picture Figure 4. Hematopoietic Agents Product Picture Figure 5. G-CSF Product Picture Figure 6. Others Product Picture Figure 7. Global Oncology Biosimilars Market Share by Application in 2020 & 2027 Figure 8. Retail Pharmacies Figure 9. Hospital Pharmacy Figure 10. Online Pharmacy Figure 11. Global Oncology Biosimilars Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 12. Global Oncology Biosimilars Market Size 2016-2027 (US$ Million) Figure 13. Global Oncology Biosimilars Sales 2016-2027 (K Units) Figure 14. Global Oncology Biosimilars Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 15. Oncology Biosimilars Sales Share by Manufacturers in 2020 Figure 16. Global Oncology Biosimilars Revenue Share by Manufacturers in 2020 Figure 17. The Global 5 and 10 Largest Oncology Biosimilars Players: Market Share by Revenue in 2020 Figure 18. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 19. Global Oncology Biosimilars Sales Market Share by Region (2016-2021) Figure 20. Global Oncology Biosimilars Sales Market Share by Region in 2020 Figure 21. Global Oncology Biosimilars Revenue Market Share by Region (2016-2021) Figure 22. Global Oncology Biosimilars Revenue Market Share by Region in 2020 Figure 23. U.S. Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. Canada Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Germany Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. France Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. U.K. Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. Italy Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Russia Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. China Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Japan Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. South Korea Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. India Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Australia Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Taiwan Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Indonesia Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Thailand Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Malaysia Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Philippines Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Vietnam Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Mexico Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Brazil Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Argentina Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Turkey Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Saudi Arabia Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. U.A.E Oncology Biosimilars Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Sales Market Share of Oncology Biosimilars by Type (2016-2021) Figure 48. Sales Market Share of Oncology Biosimilars by Application (2016-2021) Figure 49. Sales Market Share of Oncology Biosimilars by Application in 2020 Figure 50. Revenue Share of Oncology Biosimilars by Application (2016-2021) Figure 51. Revenue Share of Oncology Biosimilars by Application in 2020 Figure 52. Manufacturing Cost Structure of Oncology Biosimilars Figure 53. Manufacturing Process Analysis of Oncology Biosimilars Figure 54. Oncology Biosimilars Industrial Chain Analysis Figure 55. Channels of Distribution Figure 56. Distributors Profiles Figure 57. Bottom-up and Top-down Approaches for This Report Figure 58. Data Triangulation Figure 59. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us